Legend Biotech (LEGN) Operating Leases (2019 - 2025)

Legend Biotech's Operating Leases history runs 7 years deep, the most recent figure standing at $87.2 million for Q4 2025.

• Quarterly Operating Leases rose 95.52% year-over-year to $87.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $87.2 million (up 95.52% YoY) and the FY2025 annual result came in at $87.2 million, up 95.52% from the prior year.
• Operating Leases was $87.2 million for Q4 2025 at Legend Biotech, down from $88.1 million in the prior quarter.
• Across five years, Operating Leases topped out at $88.1 million in Q3 2025 and bottomed at $2.5 million in Q4 2021.
• A 5-year average of $48.5 million and a median of $44.5 million in 2023 frame the typical range for Operating Leases.
• Annual changes were most pronounced in 2021 — Operating Leases retreated 25.76% — and 2022, when it surged 842.57%.
• Legend Biotech's Operating Leases stood at $2.5 million in 2021, then jumped by 842.57% to $23.6 million in 2022, then surged by 87.14% to $44.2 million in 2023, then climbed by 0.98% to $44.6 million in 2024, then jumped by 95.52% to $87.2 million in 2025.
• Business Quant data shows LEGN's Operating Leases at $87.2 million in Q4 2025, $88.1 million in Q3 2025, and $71.7 million in Q2 2025.